Tranfusion independence assessed using three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes

6574 Background: The dosing schedule of azacitidine (75 mg/m2/day subcutaneous [SC] × 7 days, every 28 days) decreased transfusion requirements in myelodysplastic syndrome (MDS) patients in a CALGB...